Vertex shares fall as investors digest Crinetics acquisition and related financing plans

Vertex Pharmaceuticals (VRTX) is down 3.4% today. Here is some analysis on what might have caused this price movement.

Analysis: There does not appear to be a single new negative catalyst tied directly to today’s drop. The most likely explanation is that investors are still digesting Vertex’s recently completed Crinetics acquisition, including the integration work, the delayed financial impact, and the financing tied to the deal. This could also reflect mild profit-taking ahead of upcoming healthcare conference appearances.

Details:

Vertex completed its acquisition of Crinetics on September 1, adding the approved acromegaly drug PALSONIFY and late-stage pipeline assets in endocrine disease.

The company said the deal was worth about $10.0 billion in equity value, or about $8.8 billion net of estimated cash acquired, making it a sizable capital allocation move.

Vertex previously disclosed in its Form 10-Q a $4.5 billion delayed-draw senior unsecured term loan facility that may be used to fund part of the acquisition, which can raise near-term questions around leverage and deal economics.

Vertex also said the transaction is expected to become accretive to non-GAAP operating income in 2029, suggesting investors may be balancing long-term strategic benefits against a slower near-term payoff.

Sources:

Vertex Pharmaceuticals press release, Vertex Pharmaceuticals Form 10-Q, Vertex Pharmaceuticals investor relations

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$VRTX Insider Trading Activity

$VRTX insiders have traded $VRTX stock on the open market 14 times in the past 6 months. Of those trades, 0 have been purchases and 14 have been sales.

Here’s a breakdown of recent trading of $VRTX stock by insiders over the last 6 months:

CARMEN BOZIC (EVP and CMO) has made 0 purchases and 6 sales selling 16,740 shares for an estimated $7,566,995.
DUNCAN MCKECHNIE (EVP, Chief Commercial Officer) has made 0 purchases and 2 sales selling 4,174 shares for an estimated $2,112,118.
JOY LIU (EVP and Chief Legal Officer) has made 0 purchases and 4 sales selling 3,738 shares for an estimated $1,688,999.
OURANIA TATSIS (EVP, Chief Reg. & Quality Off.) sold 1,500 shares for an estimated $787,485
SANGEETA N. BHATIA sold 318 shares for an estimated $134,746

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

EARLY ACCESS

Receive VRTX Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$VRTX Hedge Fund Activity

We have seen 880 institutional investors add shares of $VRTX stock to their portfolio, and 813 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

JPMORGAN CHASE & CO added 6,517,600 shares (+inf%) to their portfolio in Q2 2026, for an estimated $3,237,487,448
INVESCO LTD. added 5,481,995 shares (+214.1%) to their portfolio in Q2 2026, for an estimated $2,723,071,376
FRANKLIN RESOURCES INC added 2,796,121 shares (+507.3%) to their portfolio in Q2 2026, for an estimated $1,388,917,184
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 2,041,282 shares (+inf%) to their portfolio in Q2 2026, for an estimated $1,013,966,007
CAPITAL RESEARCH GLOBAL INVESTORS removed 1,635,327 shares (-7.7%) from their portfolio in Q2 2026, for an estimated $812,315,980
VICTORY CAPITAL MANAGEMENT INC removed 1,183,614 shares (-35.3%) from their portfolio in Q2 2026, for an estimated $587,936,582
ALLIANCEBERNSTEIN L.P. removed 891,471 shares (-22.8%) from their portfolio in Q2 2026, for an estimated $442,820,389

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$VRTX Congressional Stock Trading

Members of Congress have traded $VRTX stock 2 times in the past 6 months. Of those trades, 1 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $VRTX stock by members of Congress over the last 6 months:

REPRESENTATIVE DAVID TAYLOR sold up to $15,000 on 08/26.
SENATOR ALAN ARMSTRONG purchased up to $15,000 on 03/27.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$VRTX Analyst Ratings

Wall Street analysts have issued reports on $VRTX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Maxim Group issued a "Buy" rating on 03/18/2026

To track analyst ratings and price targets for $VRTX, check out Quiver Quantitative's $VRTX forecast page.

$VRTX Price Targets

Multiple analysts have issued price targets for $VRTX recently. We have seen 7 analysts offer price targets for $VRTX in the last 6 months, with a median target of $572.0.

Here are some recent targets:

Brian Skorney from Baird set a target price of $350.0 on 07/07/2026
Brian Abrahams from RBC Capital set a target price of $570.0 on 07/07/2026
Eliana Merle from Barclays set a target price of $615.0 on 05/06/2026
Terence Flynn from Morgan Stanley set a target price of $616.0 on 05/05/2026
William Pickering from Bernstein set a target price of $572.0 on 05/05/2026
Whitney Ijem from Canaccord Genuity set a target price of $436.0 on 05/05/2026
Naz Rahman from Maxim Group set a target price of $575.0 on 03/18/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.